Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 13/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519783 | 0.85 | SPR (0.44) | SPRLMNAXDH | |
| SCHEMBL520151 | 0.84 | TGFBR1 (0.39) | ALDH1A1LMNAPOLB | |
| SCHEMBL2508645 | 0.73 | RPS6KA5 (0.38) | ALDH1A1 | |
| SCHEMBL18689758 | 0.70 | SPR (0.47) | SPR | |
| SCHEMBL28378560 | 0.67 | TGFBR1 (0.39) | ALDH1A1LMNAPOLB | |
| SCHEMBL12102104 | 0.66 | SPR (0.50) | SPR | |
| SCHEMBL29943781 | 0.66 | MEN1 (0.42) | SPRLMNA | |
| SCHEMBL18701500 | 0.66 | SPR (0.44) | SPRALDH1A1 | |
| SCHEMBL519991 | 0.65 | POLB (0.40) | GFERRXFP1ALDH1A1LMNAXDH | |
| SCHEMBL10292423 | 0.64 | PTPN1 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | SPR 3444/4885GFER 4090/4885RXFP1 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.